Fournier’s gangrene is a severe life-threatening infection involving the perianal area, perineum, and external genitalia. It demands prompt recognition, critical care therapy, surgical therapy, and a combination of antibiotics. The infection commonly spreads via the fascial planes and causes superficial vascular thrombosis within the Colles’ fascia around the external genitalia. It can extend cephalad to involve the Scarpa’s fascia and Camper’s fascia in the abdominal wall. The treatment would include multiple debridements, which would result in disfiguring scars of the perineum and might lead to significant physical and psychological complications. We describe a case of a 58-years-old man presenting with Fournier’s gangrene resulting from an infection of an impacted urethral stone. The patient previously had obstructive voiding symptoms for 1 month but chose to neglect them. The resultant infection was severe and caused penile and right testicular gangrene. He underwent multiple wound debridements, which included a total penectomy and right orchiectomy. Psychological and rehabilitative support was necessary for him to overcome his loss and disfigurement.

Introduction: Numerous novel systemic treatments have emerged for patients with primary metastatic prostate cancer (mPC), addressing both hormone-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC). However, limited understanding exists in integrating these therapies into clinical practice. This study provides an overview of mPC, presenting baseline disease characteristics, treatment profiles, and outcomes of mPC specifically in Sarawak. Materials and methods: Our study focused on registered male patients diagnosed with metastatic prostate cancer at Sarawak General Hospital between 2016 and 2023, aged over 18. Surveys were carried out during routine clinical practice, covering patient demographics, clinical parameters, primary treatments, follow-up, and outcomes. The study described treatment patterns following diagnosis. Results: Demographic and tumor profiles of 212 patients with metastatic prostate cancer in Sarawak General Hospital from 2016- 2023 were retrospectively analyzed. Patients with mPC was notably prevalent among individuals of Chinese ethnicity, accounting for 43.4% of cases, with over 50% of patients presenting with high-volume disease irrespective of ethnicity. The primary treatment modality for the majority of mPC patients was androgen deprivation therapy (ADT) alone. Among the cohort, 19.3% (n=41) experienced disease progression to metastatic castration-resistant prostate cancer (mCRPC) since 2016. Novel hormonal therapy (NHT) emerged as the predominant first-line treatment for mCRPC, administered to 53.7% of patients. Conclusion: The majority of prostate cancer patients in Sarawak are diagnosed in the metastatic stage and were of high volume at diagnosis. Aggressive treatment was initiated early in an attempt to improve treatment outcomes and overall survival.